ARRY-162
ARRY-162 is an orally bioavailable noncompetitive inhibitor of MEK1/2 and ERK that shows anticancer chemotherapeutic activity. Inhibition of MEK inhibits downstream signaling by IL-1, IL-6, and TNF. ARRY-162 inhibits proliferation in melanoma, non-small-cell lung cancer (NSCLC), head/neck cancer, and pancreatic cancer models.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18842610
| Cas No. |
606143-89-9 |
|---|---|
| Purity |
≥99% |
| Formula |
C17H15BrF2N4O3 |
| Formula Wt. |
441.23 |
| IUPAC Name |
6-(4-bromo-2-fluoroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide |
| Synonym |
MEK162 |
| Solubility |
Soluble in DMSO |
| Appearance |
White Crystal Powder |
www.clinicaltrials.gov/show/NCT00959127
